Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VVOS Vivos Therapeutics

Trading 07-22 14:50:24 EDT

0.4072

-0.0076

-1.83%

High0.4137	Low0.4037	Vol79.11K
Open0.4100	D1 Closing0.4148	Amplitude2.41%
Mkt Cap5.66M	Tradable Cap4.94M	Total Shares13.89M
T/O32.37K	T/O Rate0.65%	Tradable Shares12.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VVOS","market":"US","secType":"STK","nameCN":"Vivos Therapeutics","latestPrice":0.4072,"timestamp":1784746116608,"preClose":0.4148,"halted":0,"volume":79113,"delay":0,"changeRate":-0.018322082931533257,"floatShares":12129600,"shares":13894600,"eps":-2.120576,"marketStatus":"Trading","change":-0.0076,"latestTime":"07-22 14:50:24 EDT","open":0.41,"high":0.4137,"low":0.4037,"amount":32368.0317471,"amplitude":0.024108,"askPrice":0.4097,"askSize":100,"bidPrice":0.4046,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.120576,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784750400000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":0.4148,"postHourTrading":{"tag":"盘后","latestPrice":0.4148,"preClose":0.4148,"latestTime":"19:43 EDT","volume":68,"amount":28.5152,"timestamp":1784677434681,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8223,"impliedVol":2.594,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VVOS/wiki","defaultTab":"wiki","newsList":[{"id":"2651496833","title":"Vivos Therapeutics Discloses V-co Investors 4 as Beneficial Owner in Form 3 Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2651496833","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651496833?lang=en_us&edition=fundamental","pubTime":"2026-07-16 04:23","pubTimestamp":1784146989,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics discloses V-Co Investors 4 as beneficial owner in Form 3 filingVivos Therapeutics filed a Form 3 showing V-Co Investors 4 LLC as a 10% owner, triggered by an event dated June 30, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL9Kjk5w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650918734","title":"Vivos Therapeutics price target lowered to 75c from $1.75 at Alliance Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2650918734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650918734?lang=en_us&edition=fundamental","pubTime":"2026-07-09 02:10","pubTimestamp":1783534216,"startTime":"0","endTime":"0","summary":"Alliance Global lowered the firm’s price target on Vivos Therapeutics (VVOS) to 75c from $1.75 and keeps a Neutral rating on the shares after the c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-price-target-lowered-to-75c-from-1-75-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-price-target-lowered-to-75c-from-1-75-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649958702","title":"Vivos Therapeutics Creates New Series A Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2649958702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649958702?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:47","pubTimestamp":1783460872,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics ( ($VVOS) ) has shared an announcement. On June 30, 2026, Vivos Therapeutics raised approximately $2.1 million through a private...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-creates-new-series-a-preferred-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-creates-new-series-a-preferred-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649958102","title":"Vivos Therapeutics Files Registration Statement for PIPE Warrant, Conversion Share Resales","url":"https://stock-news.laohu8.com/highlight/detail?id=2649958102","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649958102?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:30","pubTimestamp":1783459833,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics files registration statement for PIPE warrant, conversion share resalesVivos Therapeutics filed a certificate on July 7, 2026 creating Series A Convertible Preferred Stock tied to w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL15TStp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647514615","title":"Vivos Therapeutics says Vida oral appliance improves insomnia in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2647514615","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647514615?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:35","pubTimestamp":1782826546,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics (VVOS) announced compelling clinical data showing that treatment with its FDA-cleared Vida oral appliance led to statistically s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-says-vida-oral-appliance-improves-insomnia-in-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-says-vida-oral-appliance-improves-insomnia-in-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4585","LABU","BK4196","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647556965","title":"Vivos Says Study Shows Vida Oral Appliance Cuts Insomnia Severity in All 37 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2647556965","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647556965?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:45","pubTimestamp":1782823526,"startTime":"0","endTime":"0","summary":"Vivos says study shows Vida oral appliance cuts insomnia severity in all 37 patientsVivos Therapeutics released results from a single-site clinical study run between 2022 and 2025 of its FDA-cleared V","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL7v60bN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","SG9999014005.SGD","BK4588","SG9999014039.USD","VVOS","LU2210150020.SGD","BK4112","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646381561","title":"Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2646381561","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646381561?lang=en_us&edition=fundamental","pubTime":"2026-06-26 05:49","pubTimestamp":1782424196,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics ( ($VVOS) ) has issued an announcement. On June 5, 2026, Vivos Therapeutics entered into a strategic exchange agreement with Str...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-extends-debt-for-equity-conversion-timeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-extends-debt-for-equity-conversion-timeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4585","BK4196","BK4215","EQR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646389139","title":"Vivos Therapeutics Extends Streeterville Debt-to-equity Conversion Deal Through Aug. 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646389139","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646389139?lang=en_us&edition=fundamental","pubTime":"2026-06-26 05:23","pubTimestamp":1782422600,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics extends Streeterville debt-to-equity conversion deal through Aug. 31, 2026Vivos Therapeutics extended its strategic financing agreement with Streeterville Capital through Aug. 31, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL5Z5tXS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645020385","title":"Vivos Therapeutics Extends Financing Agreement With Streeterville Through August","url":"https://stock-news.laohu8.com/highlight/detail?id=2645020385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645020385?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:23","pubTimestamp":1782134581,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics  said Monday it has extended its strategic financing agreement with Streeterville Capital through Aug. 31, giving it additional time to complete planned capital-raising efforts.Under the revised agreement, the company said Streeterville reaffirmed its commitment to convert up to $4.5 million of outstanding debt into a combination of perpetual non-convertible preferred stock and common shares.The conversion will begin once Vivos raises $2.6 million in equity and continue on a dollar-for-dollar basis up to the $4.5 million limit, the company added.Vivos said the extension would support its efforts to strengthen shareholders' equity, launch a previously announced rights offering and maintain compliance with Nasdaq listing requirements.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645229320","title":"Vivos Therapeutics extends Streeterville deal to convert up to $4.5 million debt into equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2645229320","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645229320?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:30","pubTimestamp":1782131431,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics extended its strategic financing agreement with Streeterville Capital through Aug. 31, 2026.Streeterville reaffirmed plans to convert up to USD 4.5 million of debt into perpetual, non-convertible preferred stock, common stock.Conversion starts once Vivos raises USD 2.6 million, continuing up to the USD 4.5 million cap.Extension gives more time for an equity raise, supporting stockholders’ equity strength, Nasdaq continued listing compliance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL2Z3msG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","NDAQ","VVOS","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4588","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU0314104364.USD","BK4196","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4585","BK4112","SG9999014039.USD","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022988","title":"Vivos Therapeutics - Streeterville Extends Agreement to Aug 31, 2026, Reaffirms $4.5 Mln Debt Conversion Commitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022988?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:30","pubTimestamp":1782131401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA6KTY4J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022677","title":"Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022677?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:30","pubTimestamp":1782131401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA6KTY4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644795541","title":"Vivos Therapeutics Plans Rights Offering to Existing Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2644795541","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644795541?lang=en_us&edition=fundamental","pubTime":"2026-06-17 06:26","pubTimestamp":1781648805,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics ( ($VVOS) ) has shared an update. On June 11, 2026, Vivos Therapeutics announced plans to file a registration statement with the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-plans-rights-offering-to-existing-shareholders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-plans-rights-offering-to-existing-shareholders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644981847","title":"Vivos Therapeutics plans registration statement for transferable shareholder rights offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644981847","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644981847?lang=en_us&edition=fundamental","pubTime":"2026-06-17 05:03","pubTimestamp":1781643835,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics plans to file an SEC registration statement for a rights offering that would distribute transferable subscription rights as a dividend.Rights would be issued to shareholders of record 30 days after the SEC declares the registration statement effective.Each right is expected to buy one share at the greater of USD 1.25 or 20% above the prior-day market price.Rights are expected to trade on an exchange, subject to listing requirements, with a nine-month exercise period.Exercising a right is expected to trigger a similar nine-month subsequent right priced at the greater of USD 1.75 or 40% above market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL4hjvZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643175535","title":"Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2643175535","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643175535?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:02","pubTimestamp":1781604160,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics entered a collaboration with South Palm Cardiovascular Associates to form AIM Florida, a physician-aligned management services organization.AIM Florida targets expanded diagnosis, management, and treatment support for obstructive sleep apnea and insomnia in cardiovascular patients, starting in Palm Beach County.Vivos expects to hold at least 80% of AIM Florida, with SPCVA holding up to 20%, subject to definitive agreements and regulatory requirements.Initial plan calls for one Sleep Optimization Team serving about 250 patients per month, targeting more than $6 million annual revenue with about 50% contribution margin.Structure aims to replicate Vivos’ Nevada model without acquisition-related capital outlays, with an eye toward scaling across Florida cardiology groups.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL7p68mr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642528277","title":"Vivos Therapeutics Plans to File for Proposed Rights Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642528277","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642528277?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:11","pubTimestamp":1781183486,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics  said Thursday it plans to file a registration statement with the US Securities and Exchange Commission for a proposed rights offering that would give existing shareholders the opportunity to buy additional shares.Under the proposal, the company said shareholders would receive transferable subscription rights as a dividend if the SEC declares the registration statement effective.The record date would be set 30 days after the registration statement becomes effective, the company added.Vivos Therapeutics said each right is expected to allow holders to purchase one Vivos share at the greater of $1.25 per share or a 20% premium to the market price on the day before the record date.The rights would be tradable and remain valid for nine months, the company said, adding that shareholders who exercise their rights would also receive a second tradable right, valid for nine months, to buy additional shares at the greater of $1.75 per share or a 40% premium to the market price ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642228497","title":"Vivos Therapeutics plans SEC registration filing for proposed transferable rights offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642228497","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642228497?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:31","pubTimestamp":1781181107,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics plans to file an SEC registration statement for a rights offering that would distribute transferable subscription rights as a shareholder dividend.Record date targeted for the 30th day after SEC effectiveness; timing hinges on SEC review.Each right expected to buy 1 share at the greater of USD 1.25 or 20% above the prior-day market price.Rights expected to be exchange-listed, tradeable, exercisable for 9 months.Exercise expected to trigger a similar 9-month subsequent right priced at the greater of USD 1.75 or 40% above the prior-day market price.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLc3XbK7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","BK4585","BK4112","SG9999014013.SGD","VVOS","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4196","LU2210149790.SGD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284644","title":"Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284644?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:30","pubTimestamp":1781181002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA2GFXX8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642429253","title":"Vivos Therapeutics enters pact with South Palm Cardiovascular Associates","url":"https://stock-news.laohu8.com/highlight/detail?id=2642429253","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642429253?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:18","pubTimestamp":1781097523,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics (VVOS) announced that it has entered into a collaboration agreement with South Palm Cardiovascular Associates to support the for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-enters-pact-with-south-palm-cardiovascular-associates-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-enters-pact-with-south-palm-cardiovascular-associates-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","CSII","VVOS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442937","title":"Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442937","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442937?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:04","pubTimestamp":1781096644,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics entered a collaboration with South Palm Cardiovascular Associates to form AIM Florida, a physician-aligned MSO targeting sleep apnea care in cardiac patients.Vivos expects to hold at least 80% of AIM Florida. SPCVA would hold up to 20%, subject to definitive agreements and regulatory requirements.Initial rollout targets Palm Beach County. One sleep optimization team is planned to serve about 250 patients per month.Operating plan forecasts more than USD 6 million annual revenue per team with contribution margins near 50% once fully deployed.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL8XbnGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014039.USD","LU0314104364.USD","IE00B64PRP62.GBP","BK4588","BK4585","BK4196","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2210150020.SGD","IE00BN0W2T93.GBP","VVOS","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivos.com","stockEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":-0.1704},{"period":"3month","weight":-0.5973},{"period":"6month","weight":-0.7733},{"period":"1year","weight":-0.9238},{"period":"ytd","weight":-0.7957}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.205284},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.068873},{"month":3,"riseRate":0,"avgChangeRate":-0.209794},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.183475},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.065034},{"month":6,"riseRate":0.5,"avgChangeRate":-0.015118},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.101468},{"month":8,"riseRate":0.6,"avgChangeRate":0.170604},{"month":9,"riseRate":0,"avgChangeRate":-0.252021},{"month":10,"riseRate":0.2,"avgChangeRate":-0.105489},{"month":11,"riseRate":0.4,"avgChangeRate":1.251693},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12992}],"exchange":"NASDAQ","name":"Vivos Therapeutics","nameEN":"Vivos Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivos Therapeutics,VVOS,Vivos Therapeutics股票,Vivos Therapeutics股票老虎,Vivos Therapeutics股票老虎国际,Vivos Therapeutics行情,Vivos Therapeutics股票行情,Vivos Therapeutics股价,Vivos Therapeutics股市,Vivos Therapeutics股票价格,Vivos Therapeutics股票交易,Vivos Therapeutics股票购买,Vivos Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction